Investigational Drug Details
| Drug ID: | D430 |
| Drug Name: | Febuxostat |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB04854 |
| DrugBank Description: | Febuxostat is a xanathine oxidase (XO) inhibitor indicated in patients with gout suffering from hyperuricemia and is used in its chronic management. Febuxostat is not recommended for the treatment of asymptomatic hyperuricemia. Febuxostat is marketed under the trade name Uloric by Takeda Pharmaceuticals America, Inc., and was approved by the FDA in February 2009. |
| PubChem ID: | 134018 |
| CasNo: | 144060-53-7 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N |
| Structure: |
|
| InChiKey: | BQSJTQLCZDPROO-UHFFFAOYSA-N |
| Molecular Weight: | 316.375 |
| DrugBank Targets: | Xanthine dehydrogenase/oxidase |
| DrugBank MoA: | Febuxostat, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. Febuxostat is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations. |
| DrugBank Pharmacology: | Febuxostat (ULORIC) is a novel, xanthine oxidase/dehydrogenase (XO/XDH) inhibitor being developed by Teijin, TAP Pharmaceuticals, and Ipsen for the treatment of gout. The currently available XO inhibitor, allopurinol, has been associated with serious instances of severe hypersensitivity, in some cases leading to fatalities. There is some suggestion that febuxostat is less prone to excacerbate systemic inflammatory events in animal studies. |
| DrugBank Indication: | For the treatment of hyperuricemia in patients with gout. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0012 | NCT02721342 | UNKNOWN | NO | 2009-06 | 2022-02-16 | Details | |
| L0096 | NCT00042432 | PHASE2 | COMPLETED | YES | 2002-06 | 2013-05-13 | Details |
| L0820 | NCT01026363 | WITHDRAWN | NO | 2009-12 | 2015-09-23 | Details | |
| L1065 | NCT03893799 | PHASE1 | COMPLETED | NO | 2019-08-27 | 2022-01-11 | Details |
| L1698 | NCT06185660 | COMPLETED | NO | 2024-02-09 | 2025-02-03 | Details | |
| L2300 | NCT00566865 | PHASE1 | COMPLETED | NO | 2007-11 | 2009-02-18 | Details |
| L2769 | NCT00964262 | PHASE1 | COMPLETED | NO | 2009-08 | 2013-07-19 | Details |
| L2782 | NCT00608101 | WITHDRAWN | NO | 2010-09 | 2014-12-11 | Details | |
| L7213 | NCT01076647 | PHASE3 | COMPLETED | YES | 2010-03 | 2017-03-06 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|